FDA eye drug rebuff adds to Shire's woes in Baxalta pursuit
0
(Reuters) - Shire Plc suffered a setback for its most important pipeline medicine late on Friday, adding to the group's problems as it pursues Baxalta Inc to forge the leading global specialist in rare diseases.